Hu Duan

Dr. Duan earned his Ph.D. in Biomedical Sciences from Arizona State University from September 2009 to July 2015. Since March 2016, he has been serving as the General Manager of Beijing Taige Kexin Biotechnology Co., Ltd. Dr. Duan is a Council Member of the Wuhan University Health Industry Alliance, a Standing Committee Member of the Youth Entrepreneurs Committee of the Medical Laboratory Industry Branch, National Association of Health Industry and Enterprise Management (NAHIEM), a Committee Member of the China Medical Equipment Procurement and Management Expert Committee, and a Committee Member of the Experimental Medicine (Translational) Specialty Committee of NAHIEM. Dr. Duan has long been engaged in proteomics and in vitro diagnostic technology innovation, with a focus on high-throughput protein microarrays, clinical quantitative detection, and biomarker development. He was trained under Professor Leland Hartwell, the 2001 Nobel Laureate in Physiology or Medicine. His research is centered on clinical translation and has established cutting-edge technology platforms including cell-free expressed protein arrays and multiplex nucleic acid-programmable protein arrays, enabling high-throughput and precise screening of tumor markers, autoantibody markers, and viral antigens and antibodies. He has applied proteomic technologies to early screening of major diseases and infectious disease diagnosis, developing systems such as bead-based immunoassay for tumor marker glycosylation profiling and red blood cell membrane antigen arrays, overcoming the limitations of conventional methods in throughput and specificity. During the COVID-19 pandemic, based on comprehensive viral proteome profiling, he rapidly developed antibody and antigen diagnostic reagents, supporting public health emergency responses. His related findings have been published in prestigious journals including Theranostics and ACS Central Science. Multiple technologies have been successfully translated into industrial applications, advancing proteomics from basic research to clinical implementation and providing critical technical support for precision medicine and the upgrading of the in vitro diagnostic industry.

Selected publications:
1.Multiplexed Nucleic Acid Programmable Protein Arrays. Theranostics, 2017. (Lead author)
2.Advances in cell-free protein array methods. Expert Review of Proteomics, 2018. (Lead author)
3.Development of RBC membrane antigen arrays. Journal of Proteome Research, 2018. (Lead author)
4.Serum protein profiling reveals a landscape of inflammation and immune signaling in early-stage COVID-19 infection. Molecular & Cellular Proteomics, 2020. (Lead author)
5.Glycosylation Profiling of Tumor Marker in Plasma Using Bead-Based Immunoassay. Methods in Molecular Biology, 2019.